Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Ratios

Hinge Health (HNGE) Change in Accured Expenses (2024 - 2026)

Hinge Health's Change in Accured Expenses history spans 2 years, with the latest figure at $67.7 million for Q4 2025.

On a quarterly basis, Change in Accured Expenses rose 304.92% to $67.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $29.6 million, a N/A change, with the full-year FY2025 number at $29.4 million, up 367.95% from a year prior.
Change in Accured Expenses hit $67.7 million in Q4 2025 for Hinge Health, up from -$45.3 million in the prior quarter.
Over the last five years, Change in Accured Expenses for HNGE hit a ceiling of $67.7 million in Q4 2025 and a floor of -$45.3 million in Q3 2025.